Bangkok Genomics Innovation Public Company Limited
2.38
THB
+0.06
(+2.59%)
ISIN
THB972010003
Return %
Stock
S&P 500
1Y
48.75
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
THB
•
in mil. unless spec.Working Capital
THB
•
in mil. unless spec.Growth Rates
THB
•
in mil. unless spec.Quarterly Revenue
THB
•
in mil. unless spec.Quarterly Earnings Per Share
THB
•
in mil. unless spec.Quarterly Dividends Per Share
THB
•
in mil. unless spec.Company Description
- CEO
- Saowalak Dansakul
- Full Time Employees
- 37
- Sector
- Commercial services
- Industry
- Miscellaneous commercial services
- Address
- 3689 Rama 4 Road Bangkok BM Thailand 10110
- IPO Date
- Mar 20, 2024
- Website
- bangkokgenomics.com
- Similar Companies
- Business
- Bangkok Genomics Innovation Public Company Limited (BKGI.BK), founded in 2017 and headquartered in Bangkok, Thailand, operates as a subsidiary of BGI Genomics and provides medical laboratory testing and genomic analysis services primarily in Thailand. The company offers reproductive health screening including non-invasive prenatal testing (NIPT) for fetal chromosomal abnormalities under the NIFTY brand, preimplantation genetic testing (PGT-A) and thalassemia carrier screening under the VISTA brand, infectious disease testing such as COVID-19, monkeypox, HPV and SARS-CoV-2 serology, cancer-related genetic screening including hereditary cancer risk (SENTIS HDC) and colorectal cancer under COLOTECH, individual genetic analysis under DNALL for personalized diet, exercise and anti-aging, newborn screening, Alzheimer's and neurodegenerative disease screening, health check-ups, tech solutions like DNA/RNA sequencing, metabolomics and proteomics, and medical products including genetic sequencers, real-time PCR kits and cell-free DNA storage tubes; it serves government entities like medical schools and health centers alongside private clinics, hospitals, laboratories and research institutes. In 2025, BKGI signed an MOU with Eisai (Thailand) for Alzheimer's screening integration on January 9, a strategic partnership with MGI Tech on April 28 to expand NGS platform access, a letter of intent with the Agricultural Research Development Agency on April 29 for agricultural innovation, an intellectual property agreement with Chulalongkorn University on May 15 for CAR-T cell therapy development, and a service contract with the Institute of Medical Research on June 27 for biological age assessment research; earlier in 2024, it executed MOUs with Bumrungrad International Hospital and BGI Shenzhen for genomic medicine advancement and with the Department of Medical Sciences for knowledge exchange.